Comprehensive Molecular Characterization of Chinese Patients with Glioma by Extensive Next-Generation Sequencing Panel Analysis
Chun Zeng,Jing Wang,Mingwei Li,Huina Wang,Feng Lou,Shanbo Cao,Changyu Lu
DOI: https://doi.org/10.2147/CMAR.S291681
2021-04-30
Cancer Management and Research
Abstract:Chun Zeng, 1, 2 Jing Wang, 3 Mingwei Li, 4 Huina Wang, 4 Feng Lou, 4 Shanbo Cao, 4 Changyu Lu 3 1 Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China; 2 China National Clinical Research Center for Neurological Diseases, Beijing, People's Republic of China; 3 Department of Neurosurgery, Peking University International Hospital, Beijing, People's Republic of China; 4 Acornmed Biotechnology Co., Ltd, Beijing, People's Republic of China Correspondence: Changyu Lu Department of Neurosurgery, Peking University International Hospital, Beijing, People's Republic of China Tel +8669006144 Email Shanbo Cao Acornmed Biotechnology Co., Ltd, Floor 18, Block 5, Yard 18, Kechuang 13 Road, Beijing, 100176, People's Republic of China Tel +8653606156 Email Background: Tremendous efforts have been made to explore biomarkers for classifying and grading glioma. However, the majority of the current understanding is based on public databases that might not accurately reflect the Asian population. Here, we investigated the genetic landscape of Chinese glioma patients using a validated multigene next-generation sequencing (NGS) panel to provide a strong rationale for the future classification and prognosis of glioma in this population. Methods: We analyzed 83 samples, consisting of 71 initial treatments and 12 recurrent surgical tumors, from 81 Chinese patients with gliomas by performing multigene NGS with an Acornmed panel targeting 808 cancer-related hotspot genes, including genes related to glioma (hotspots, selected exons or complete coding sequences) and full-length SNPs located on chromosomes 1 and 19. Results: A total of 76 (91.57%) glioma samples had at least one somatic mutation. The most commonly mutated genes were TP53, TERT, IDH1, PTEN, ATRX , and EGFR . Approximately one-third of cases exhibited more than one copy number variation. Of note, this study identified the amplification of genes, such as EGFR and PDGFRA , which were significantly associated with glioblastoma but had not been previously used for clinical classification (P< 0.05). Significant differences in genomic profiles between different pathological subtypes and WHO grade were observed. Compared to the MSKCC database primarily comprised of Caucasians, H3F3A mutations and MET amplifications exhibited higher mutation rates, whereas TERT mutations and EGFR and CDKN2A/B copy number variations presented a lower mutation rate in Chinese patients with glioma (P< 0.05). Conclusion: Our multigene NGS in the simultaneous evaluation of multiple relevant markers revealed several novel genetic alterations in Chinese patients with glioma. NGS-based molecular analysis is a reliable and effective method for diagnosing brain tumors, assisting clinicians in evaluating additional potential therapeutic options, such as targeted therapy, for glioma patients in different racial/ethnic groups. Keywords: glioma, molecular pathology, molecular biomarker, copy number variations, multigene NGS panel Gliomas are the most common tumors in the brain and central nervous system (CNS). 1 However, gliomas comprise a diverse collection of entities, each with its own unique clinical and biological characteristics. 2 According to the 2016 World Health Organization (WHO) standards, gliomas include grade II–III astrocytoma (A) and oligodendroglioma (O), as well as grade IV glioblastoma (GBM) and diffuse midline glioma (DMG). 3 Previous brain tumor classification was primarily based on histopathological characteristics confirmed by hematoxylin and eosin staining (H&E) and immunohistochemistry (IHC). Detection of IDH mutations, 1p/19q codeletion, and H3F3A mutations (midline position) are now recommended according to their histologic diagnosis. 4–6 Emerging evidence has shown that inclusion of molecular characterization could improve the prognostic and predictive stratification of CNS tumors. 7–9 In fact, many key mutations in the TERT, ATRX, TP53 , and EGFR genes found in gliomas 10 , 11 could be used as diagnostic, prognostic, and therapeutic biomarkers. However, these mutation markers have not been included in the latest WHO CNS tumor classification criteria; 3 therefore, they are not used in ro -Abstract Truncated-
oncology